<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-section" /><meta name="keywords" content="Immunosuppressants: skin disease; Pimecrolimus; Tacrolimus: eczema; Ciclosporin: eczema; Ciclosporin: psoriasis; Azathioprine: eczema; Mycophenolate mofetil: eczema; Methotrexate: psoriasis; Cytokine modulators: psoriasis; Etanercept: psoriasis; Adalimumab: psoriasis; Infliximab: psoriasis; Ustekinumab" /><meta name="IX" content="Immunosuppressants: skin disease; Pimecrolimus; Tacrolimus: eczema; Ciclosporin: eczema; Ciclosporin: psoriasis; Azathioprine: eczema; Mycophenolate mofetil: eczema; Methotrexate: psoriasis; Cytokine modulators: psoriasis; Etanercept: psoriasis; Adalimumab: psoriasis; Infliximab: psoriasis; Ustekinumab" /><title>13.5.3 Drugs affecting the immune response: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="106473.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="106473.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=106473.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2080.htm">13 Skin</a> &gt; <a href="5937.htm">13.5 Preparations for eczema and psoriasis</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="5995.htm" title="Previous: ACITRETIN">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="204280.htm" title="Next: AZATHIOPRINE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_106473">13.5.3 Drugs affecting the immune response</h1><?highlighter on?><div id="pC" class="jN"><div><p>Drugs affecting the immune response are used
for eczema or psoriasis. Systemic drugs acting on the immune system
are used under specialist supervision. </p><div id="_106473.1"><p><b><span>Pimecrolimus</span></b> by topical application is licensed
for <i>mild to moderate atopic eczema</i>. <b><span>Tacrolimus</span></b> is licensed for topical use in <i>moderate to severe atopic
eczema</i>. Both are drugs whose long-term safety is still being
evaluated and they should not usually be considered first-line treatments
unless there is a specific reason to avoid or reduce the use of topical
corticosteroids. Treatment with topical pimecrolimus or topical tacrolimus
should be initiated only by prescribers experienced in treating atopic
eczema</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Tacrolimus and pimecrolimus for atopic eczema (August
2004)</h3><p>Topical pimecrolimus and tacrolimus are options for atopic eczema
not controlled by maximal topical corticosteroid treatment or if there
is a risk of important corticosteroid side-effects (particularly skin
atrophy).</p><p>Topical pimecrolimus is recommended for moderate atopic eczema
on the face and neck of children aged 2–16 years and topical tacrolimus
is recommended for moderate to severe atopic eczema in adults and
children over 2 years. Pimecrolimus and tacrolimus should be used
within their licensed indications.</p></div><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (March 2010) that tacrolimus ointment (<span class="cZ">Protopic</span>®) is accepted for restricted use within NHS Scotland for the prevention
of flares in those with moderate to severe atopic eczema in accordance
with the licensed indications; its use is restricted to initiation
by doctors (including general practitioners) with specialist interest
and experience in treating atopic eczema with immunomodulatory therapy.</p><p>For the role of topical corticosteroids in eczema, see <a title="target-block: corticosteroids: eczema" href="5938.htm#_1.8">section 13.5.1</a>, and for their role in psoriasis,
see <a title="BNF:sub-section: Preparations for psoriasis" href="5974.htm#_5974">section 13.5.2</a>. A short
course of a systemic corticosteroid (section 6.3.2) can be given for
eczema flares that have not improved despite appropriate topical treatment.</p><p><b><span>Ciclosporin</span></b> by mouth can be used for <i>severe psoriasis</i> and for <i>severe eczema</i>. <b><span>Azathioprine</span></b> or <b><span>mycophenolate mofetil</span></b> (<a title="monograph: MYCOPHENOLATE MOFETIL" href="38696.htm#_38696">section 8.2.1</a>) are used for severe refractory
eczema [unlicensed indication].</p><div id="_202252"><p><b><span>Methotrexate</span></b> can be used for <i>severe psoriasis</i>, the
dose being adjusted according to severity of the condition and haematological
and biochemical measurements. Folic acid 5 mg (<a title="monograph: FOLIC ACID" href="4906.htm#_4906">section 9.1.2</a>) can be given once weekly [unlicensed indication],
on a different day from the methotrexate, to reduce the possibility
of side-effects associated with methotrexate; alternative regimens
of folic acid may be used in some settings.</p></div><div id="_201034"><p><b>Etanercept</b>, <b>adalimumab</b>, and <b>infliximab</b> inhibit
the activity of tumour necrosis factor (TNFα). They are used for <i>severe plaque psoriasis</i> either refractory to at least 2
standard systemic treatments and photochemotherapy, or when standard
treatments cannot be used because of intolerance or contra-indications;
while either etanercept or adalimumab is considered to be the first
choice in stable disease, infliximab or adalimumab may be useful when
rapid disease control is required. <b>Ustekinumab</b> (a monoclonal antibody that inhibits
interleukins 12 and 23) can be used for <i>severe plaque psoriasis</i> that has not responded to at least 2 standard systemic treatments
and photochemotherapy, or when these treatments cannot be used because
of intolerance or contra-indications (see also NICE guidance below).
Adalimumab, etanercept, and infliximab are also licensed for psoriatic
arthritis (<a title="BNF:monograph-family: Cytokine modulators" href="202659.htm#_202659">section 10.1.3</a>).</p><div class="cN"><h2 class="cBR">NICE guidance<sup class="footnote"><a title="Go to footnote" href="106473.htm#footnote201647">(1)</a></sup></h2><h3 class="cBP">Adalimumab for plaque psoriasis in adults (June 2008)</h3><p>Adalimumab is recommended for the treatment of severe plaque
psoriasis which has failed to respond to standard systemic treatments
(including ciclosporin and methotrexate) and photochemotherapy, or
when standard treatments cannot be used because of intolerance or
contra-indications. Adalimumab should be withdrawn if the response
is not adequate after 16 weeks.</p></div><div class="cN"><h2 class="cBR">NICE guidance<sup class="footnote"><a title="Go to footnote" href="106473.htm#footnote204102">(2)</a></sup></h2><h3 class="cBP">Etanercept and efalizumab for plaque psoriasis in
adults (July 2006)</h3><p>Etanercept is recommended for severe plaque psoriasis which
has failed to respond to standard systemic treatments (including ciclosporin
and methotrexate) and to photochemotherapy, or when standard treatments
cannot be used because of intolerance or contra-indications. Etanercept
should be withdrawn if the response is not adequate after 12 weeks.</p><p>Following suspension of the marketing authorisation for efalizumab,
NICE has temporarily withdrawn its guidance on the use of efalizumab
for plaque psoriasis.</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Infliximab for plaque psoriasis in adults (January
2008)</h3><p>Infliximab is recommended for the treatment of very severe plaque
psoriasis which has failed to respond to standard systemic treatments
(including ciclosporin and methotrexate) or to photochemotherapy,
or when standard treatments cannot be used because of intolerance
or contra-indications. Infliximab should be withdrawn if the response
is not adequate after 10 weeks.</p></div><div class="cN"><h2 class="cBQ">NICE Guidance</h2><h3 class="cBP">Ustekinumab for plaque psoriasis in adults (September
2009)</h3><p>Ustekinumab is recommended for the treatment of severe plaque
psoriasis which has failed to respond to standard systemic treatments
(including ciclosporin and methotrexate) and to photochemotherapy,
or when standard treatments cannot be used because of intolerance
or contra-indications. Ustekinumab should be withdrawn if the response
is not adequate after 16 weeks.</p><p>For patients weighing over 100 kg, the manufacturer should provide
the 90-mg dose of ustekinumab at the same price as the 45-mg dose</p></div></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_204280"><a href="204280.htm" title="AZATHIOPRINE">AZATHIOPRINE</a></li><li id="_6000"><a href="6000.htm" title="CICLOSPORIN">CICLOSPORIN</a></li><li id="_6002"><a href="6002.htm" title="METHOTREXATE">METHOTREXATE</a></li><li id="_119691"><a href="119691.htm" title="PIMECROLIMUS">PIMECROLIMUS</a></li><li id="_119635"><a href="119635.htm" title="TACROLIMUS">TACROLIMUS</a></li><li id="_201650"><a href="201650.htm" title="Cytokine modulators">Cytokine modulators</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="5995.htm">Previous: ACITRETIN</a> | <a class="top" href="106473.htm#">Top</a> | <a accesskey="]" href="204280.htm">Next: AZATHIOPRINE</a> ►</div><div class="cF"><div class="footnote" id="footnote201647"><sup>(1)</sup>The <i>Scottish Medicines Consortium</i> issued similar
advice in May 2008.</div><div class="footnote" id="footnote204102"><sup>(2)</sup>The <i>Scottish Medicines Consortium</i> issued similar
advice (August 2009) on the use of etanercept in adults and children
over 8 years of age</div></div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>